XTX Topco’s Checkpoint Therapeutics CKPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-72,766
Closed -$294K 2450
2025
Q1
$294K Buy
+72,766
New +$243K 0.02% 1425
2024
Q4
Sell
-18,033
Closed -$40.4K 2367
2024
Q3
$40.4K Buy
18,033
+2,428
+16% +$5.6K ﹤0.01% 1724
2024
Q2
$33.6K Buy
+15,605
New +$27.8K ﹤0.01% 1551
2023
Q4
Sell
-20,941
Closed -$35.6K 1661
2023
Q3
$35.6K Buy
+20,941
New +$47.6K 0.01% 1318
2023
Q2
Sell
-10,125
Closed -$22.8K 1459
2023
Q1
$22.8K Buy
+10,125
New +$50.8K ﹤0.01% 1207
2021
Q3
Sell
-1,622
Closed -$48K 736
2021
Q2
$48K Buy
1,622
+438
+37% +$12.1K 0.02% 728
2021
Q1
$37K Buy
+1,184
New +$39.7K 0.02% 638

XTX Topco's CKPT Position: Q2 2025 in Review

XTX Topco sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 72,766 shares — an estimated $294K sold.

XTX Topco first reported a position in CKPT in Q1 2021 and held it in 7 quarters. The position peaked at $294K in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

  • XTX Topco reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 72,766 Checkpoint Therapeutics shares in Q2 2025, an estimated $294K.
  • XTX Topco first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 7 quarters.
  • XTX Topco's Checkpoint Therapeutics position peaked at $294K in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.